Verona Pharma plc Sponsored ADR Stock

$68.84

5.17% yesterday

Nasdaq, Apr 28, 10:15 pm CET

ISIN

US9250501064

Symbol

VRNA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Verona Pharma plc Sponsored ADR Stock price

$68.83

+62.84 1,049.08% 5Y

Nasdaq, Closing price Mon, Apr 28 2025

+3.37 5.15%

ISIN

US9250501064

Symbol

VRNA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$5.54b
Enterprise Value	$5.26b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	125.30
P/S ratio (TTM) P/S ratio	131.90
P/B ratio (TTM) P/B ratio	27.08
Revenue (TTM) Revenue	$42.00m
EBIT (operating result TTM) EBIT	$-154.94m
Free Cash Flow (TTM) Free Cash Flow	$-122.83m
Cash position	$399.76m
EPS (TTM) EPS	$-2.16
P/E forward	596.90
P/S forward	17.54
EV/Sales forward	16.66
Short interest	9.54%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Verona Pharma plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

10x Buy

100%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Verona Pharma plc Sponsored ADR forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Verona Pharma plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	42 42	- 100%
- Direct Costs	3.63 3.63	434% 434% 9%
Gross Profit	38 38	5,743% 5,743% 91%
- Selling and Administrative Expenses	148 148	200% 200% 351%
- Research and Development Expense	45 45	157% 157% 106%
EBITDA	-154 -154	129% 129% -366%
- Depreciation and Amortization	1.06 1.06	56% 56% 3%
EBIT (Operating Income) EBIT	-155 -155	128% 128% -369%
Net Profit	-174 -174	218% 218% -413%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Verona Pharma plc Sponsored ADR Stock News

Positive

Seeking Alpha

●

21 days ago

Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical

Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose c...

Neutral

GlobeNewsWire

●

about one month ago

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repay...

Neutral

Seeking Alpha

●

2 months ago

Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript

Verona Pharma plc (NASDAQ:VRNA ) Q4 2024 Earnings Conference Call February 27, 2024 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Tiago Fauth - Wells Fargo Tom Shrader - BTIG Ram Selvaraju - HCW Joon Lee - Truist Boobalan Pachaiyappan - ROTH Operat...

More Verona Pharma plc Sponsored ADR News

Company Profile

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Head office	United Kingdom
CEO	David Zaccardelli
Employees	209
Founded	2005
Website	www.veronapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now